TY - JOUR
T1 - The nature of early-stage endometrial cancer recurrence
T2 - a national cohort study
AU - Jeppesen, Mette Moustgaard
AU - Jensen, Pernille Tine
AU - Gilså Hansen, Dorte
AU - Iachina, Maria
AU - Mogensen, Ole
PY - 2016/12
Y1 - 2016/12
N2 - Background and aims The aim of the study was to present a comprehensive analysis of disease recurrence in a large Danish cohort of women with early-stage endometrial cancer treated according to national guidelines. Methods All women diagnosed with stage I or II endometrial cancer in 2005–2009 were included in a population-based historical cohort derived from the Danish Gynaecological Cancer Database. Disease recurrence up to 3 years after the primary diagnosis was identified using national registers and hospital charts. Follow-up on survival ended on 31st December 2014. We evaluated the predictive value of clinico-pathological and sociodemographic variables using multivariate logistic regression. Results Recurrence within 3 years of the primary treatment was diagnosed in 183 (7%) of the included 2612 women. Site of recurrence significantly impacted on overall survival as the 5-year survival rate was 64.8% for women with vaginal recurrence and 17.5% in women with distant recurrence. Factors predictive of recurrence included the International Federation of Gynaecology and Obstetrics (FIGO) stage (OR: IB = 1.91, stage II = 3.91), Charlson comorbidity index of 3 (OR 1.86), non-endometrioid histology (OR 1.81) and being outside of the workforce (OR 1.81). Vaginal recurrence was predicted by FIGO stage only (OR: IB = 1.88, II = 2.79), while extra-vaginal recurrence was predicted by FIGO stage (OR: IB = 2.12, II = 3.31), Charlson comorbidity index of 3 (OR 1.88) and non-endometrioid histology (OR 2.51). Conclusions Future research should seek to understand the underlying mechanisms of the identified predictive factors to improve recurrence prediction and to reduce morbidity and mortality.
AB - Background and aims The aim of the study was to present a comprehensive analysis of disease recurrence in a large Danish cohort of women with early-stage endometrial cancer treated according to national guidelines. Methods All women diagnosed with stage I or II endometrial cancer in 2005–2009 were included in a population-based historical cohort derived from the Danish Gynaecological Cancer Database. Disease recurrence up to 3 years after the primary diagnosis was identified using national registers and hospital charts. Follow-up on survival ended on 31st December 2014. We evaluated the predictive value of clinico-pathological and sociodemographic variables using multivariate logistic regression. Results Recurrence within 3 years of the primary treatment was diagnosed in 183 (7%) of the included 2612 women. Site of recurrence significantly impacted on overall survival as the 5-year survival rate was 64.8% for women with vaginal recurrence and 17.5% in women with distant recurrence. Factors predictive of recurrence included the International Federation of Gynaecology and Obstetrics (FIGO) stage (OR: IB = 1.91, stage II = 3.91), Charlson comorbidity index of 3 (OR 1.86), non-endometrioid histology (OR 1.81) and being outside of the workforce (OR 1.81). Vaginal recurrence was predicted by FIGO stage only (OR: IB = 1.88, II = 2.79), while extra-vaginal recurrence was predicted by FIGO stage (OR: IB = 2.12, II = 3.31), Charlson comorbidity index of 3 (OR 1.88) and non-endometrioid histology (OR 2.51). Conclusions Future research should seek to understand the underlying mechanisms of the identified predictive factors to improve recurrence prediction and to reduce morbidity and mortality.
KW - Disease recurrence
KW - Endometrial carcinoma
KW - Gynaecological malignancy
KW - RSS
KW - Relapse
KW - Risk stratification
KW - Lymph Node Excision
KW - Multivariate Analysis
KW - Vagina/pathology
KW - Age Factors
KW - Humans
KW - Middle Aged
KW - Chemoradiotherapy, Adjuvant
KW - Pelvis
KW - Carcinoma, Endometrioid/epidemiology
KW - Time Factors
KW - Female
KW - Chemotherapy, Adjuvant
KW - Carcinoma, Adenosquamous/epidemiology
KW - Radiotherapy, Adjuvant
KW - Body Mass Index
KW - Ovariectomy
KW - Comorbidity
KW - Endometrial Neoplasms/therapy
KW - Risk Factors
KW - Adenocarcinoma, Clear Cell/epidemiology
KW - Neoplasm Recurrence, Local/epidemiology
KW - Logistic Models
KW - Survival Rate
KW - Salpingectomy
KW - Sick Leave/statistics & numerical data
KW - Hysterectomy
KW - Smoking/epidemiology
KW - Denmark/epidemiology
KW - Retirement/statistics & numerical data
KW - Lymph Nodes/pathology
KW - Aged
KW - Unemployment/statistics & numerical data
KW - Neoplasm Staging
KW - Carcinosarcoma/epidemiology
KW - Neoplasms, Cystic, Mucinous, and Serous/epidemiology
U2 - 10.1016/j.ejca.2016.09.033
DO - 10.1016/j.ejca.2016.09.033
M3 - Journal article
C2 - 27816832
SN - 0959-8049
VL - 69
SP - 51
EP - 60
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - December
ER -